Saturday, October 08, 2005

Reviewing the theory of a thimerosal based etiology for the autism spectrum: A partial review of Generation Rescue's 25 myths

I was reluctant to begin this post. The thimerosal debate is not very friendly. Also, bad things can happen when we leave our area of knowledge and trod into someone else’s. I am not a medical student or toxicologist. I have only a very novice understanding of chemistry. All the same I can and do have a knowledge base in epidemiology and in research design. The thimerosal argument can not be effectively made in the absence of the previous two disciplines. I will focus my critique on these points.

I thought the best way to focus on this will be to look at certain myths in Generation Rescue’s “25 Mercury Myths” (Generation Rescue, 2005).


Myth 1

“There is no evidence to suggest that autism is genetic. No autism gene has ever been found and the search will be endless - how can you have a gene for a mythical condition? Autism is mercury poisoning. What is true is that certain children may have an impaired ability genetically to detoxify heavy metals from their systems. These children are more likely to be affected by mercury exposure. However, all children, and adults, if given too much mercury will manifest symptoms of mercury toxicity, which we call "autistic" symptoms. All children born from 1991 forward who received all recommended vaccines were injected with levels of mercury that dramatically exceeded safety levels set by the Environmental Protection Agency for adults. Mercury has become ubiquitous in our environment: in fish and other foods, water, and air. Exceedingly high doses of mercury exposure can result in death - it is that neuro-toxic and damaging to the human body. Two drops of dimethylmercury spilled onto the gloved hand of a Dartmouth chemistry professor, a leader in a study investigating mercury's causal role in cancer, resulting in the progressive loss of her balance, speech, vision, and hearing, and ultimately lead to her coma and death within a year of the exposure.”

No gene has been found which causes autism, that is correct. If autism is mythical why does there seem to be certain cognitive traits (strengths and weaknesses) that have been identified in the research. Is this a departure from what is known about other heavy metal toxicity? Why do older persons who have been exposed to mercury not receive the diagnostic of autism then, it seems there are important dissimilarities.

“It is impossible to have a "genetic epidemic." Since 1991, there is a very real and dramatic rise in the incidence of autism and other neurodevelopmental disorders. In the 1970s, the incidence of autism was 1 in 10,000 children. In 1986, the rate was 1 in 2,500. Today the rate is 1 in 150. It has been estimated that one in six children have some type of learning disability. Epidemics can happen in 10 years, genetic changes to populations require many generations.”

Where is the increase evidenced? Depending on the data, this may or may not be valid, the definition does not attempt to answer for other factors such as change in criteria, increased knowledge, and more precise diagnostic tools. In the 1970s the mean prevalence for autism was (3.27) per 10,000 by the way; if we include the whole autism spectrum then we have 13.7 per 10,000. Also, the present prevalence is probably best described as 1 in 166. While genetic changes take many generations, perhaps knowledge of the various ways of being human take even longer.

Myth 2

“There is a growing body of evidence that children properly treated for mercury poisoning fully recover normal functioning and are indiscernible from their neurotypical peers. Any toxicologist will tell you that mercury poisoning represents a temporary, treatable state. Thorough removal of mercury will resolve most or all of the symptoms. Autism is only life long if mercury poisoning is never treated”

This would be the appropriate time to cite peer reviewed research clearly demonstrating this, this is absent.

Myth 6

“This myth persists despite being refuted by a wide range of scientists, policy makers, and health care organizations. All the available data points to an epidemic. Between 1992-2002, the Department of Education estimates that there has been a 714% increase in the number of autistic children. In the 1970s, autism was estimated to occur in 1 in 25,000 children. Between 1970 and 1990, that number increased to about 1 in 2,500. Today, the CDC acknowledges the number is about 1 in 166, even Eli Lilly, the maker of Thimerosal, says it's 1 in 150. Many believe it is closer to 1 in 125. The anecdotal evidence that we are experiencing an epidemic is overwhelming. If there is no epidemic, then where are all the autistic adults? Ask any doctor, teacher, or day care worker who has been around children for 20 or more years, and they will tell you that the epidemic is unprecedented. What parent, either now or 20 years ago, does not notice that their child who spoke at one year is no longer speaking, or that their child does not respond to their name or look them in the eyes, or is displaying odd, repetitive behaviors like hand-flapping, spinning, and rocking that no other child is doing? Did those parents 20 years ago not notice these things?”

Where is this refuted via research? I have dedicated other posts to why the education data should never have been used to track prevalence or incidence. A Photon In the Darkness (2005) points out that the plural of anecdote is not data. By the way what was the average age of diagnosis twenty years ago; maybe we are not always as good of observers as we think. Also, twenty years ago Autism was a new diagnosis (placed in DSM-III, 1980).

Myth 8

“The symptoms of autism and other neurodevelopmental disorders are identical to the symptoms of mercury poisoning. The rapid rise in the number of these disorders corresponds to the dramatic increase in the amount of Thimerosal (49.6% ethylmercury by weight) given in recommended vaccines to children under two years of age. With the addition of two new vaccines in the early 1990s, the amount of ethylmercury increased 246% with most of this increase being given within the first six months of life when an infant's neural, detoxification, and immune systems are all undergoing rapid development. Equally damaging, the vaccines were given much earlier in a child's life, when the capacity to detoxify is still developing. Numerous studies demonstrate again and again the causal link between neurodevelopmental disorders and mercury, regardless of the source of exposure. Finally and most definitively of all is that when mercury is removed from these children via chelation or other means of detoxification, their symptoms resolve.”

There seems to be important differences, such as the shaking that is seen in mercury poisoning. Again correlation is not causation, there are other correlates as well. No study demonstrates the causal link between autism and mercury, this is in part because, such would never get past an ethics review board. Where is the research?

Myth 15

“You could analyze the data the government maintains through its "Vaccine Adverse Events Reporting System" and compare the data they already have on children who received Thimerosal-containing vaccines against children who did not receive Thimerosal in their vaccines. This study has already been done by Mark & David Geier and showed a high correlation between Thimerosal dosing and neurological disorders:”

Correlation is not causation.

“You could compare the symptoms of mercury poisoning and the symptoms of autism and see how similar they are. This study has already been done and demonstrated that the symptoms of autism and the symptoms of mercury poisoning are exactly the same:”

Except for the instances where they are not similar.

“You could administer a chelating agent to remove heavy metals, including mercury, to a group of autistic children and to a group of neurotypical children and measure the amount of mercury coming out of the children to see if there are any differences. This study has already been done by Jeff Bradstreet et.al. and showed that autistic children excrete significantly more mercury than neurotypical children:”

Yes, but that does not mean mercury caused the autism. Also, a more equivalent control sample would have been desirable.

Myth 16
“You could inject a group of mice with Thimerosal in doses that proportionally mimic the timing and amount received according to the recommended vaccination schedule and compare these mice to a control group for neurological development. This study has already been done by Mady Hornig et al. and showed that a subset of mice with genetic detoxification impairments who received Thimerosal injections developed "autistic symptoms":”

To my knowledge we have no protocol for identifying autistic mice.

“You could run a trial of 31 autistic children where you chelated patients over the course of twelve months and had parents videotape their children and test urine and fecal samples for toxic metals every other month. You could then compare the children's progress and symptoms from the beginning to the end of treatment. This study was done by Dr. Rashid Buttar and he made the following statement before Congress.”

The videotape is not sufficient to show causation, this is due to observer drift. This also never made it to a peer reviewed journal.

Myth 16

“Generation Rescue believes autism is an issue of toxicology. Yet, you never hear from a toxicologist saying there is no correlation between autism and mercury. This is because toxicologists know that the link is likely. Hearing a psychiatrist comment on mercury toxicity is like seeking the opinion of a urologist for a new heart procedure. It doesn't make sense to accept the expertise of people who have no experience in the field of heavy metal to.”

Anyone can make a criticism, the criticism has to stand on its own merit. Same goes
for the validity of an experts opinion, it has to stand on its own merit.



Myth 19

“In May 2004, the Institute of Medicine released a 216-page report titled Immunization Safety Review: Vaccines and Autism and concluded that there did not appear to be a causal link between Thimerosal and the autism epidemic. This study was paid for by the CDC, a conflict in of itself, and there is growing evidence that the conclusion was pre-ordained before any research was done. Regarding the potential link between mercury and autism, Dr. Marie McCormick, Committee Chair of the IOM study, in a recently released transcript, stated (before any research had been done), "We are not ever going to come down that it is a true side effect." Much of the IOM's conclusion was based on the aforementioned CDC and Danish studies - there was no primary research done. This lack of new, primary research is a critical point: the IOM's conclusion was largely based on the studies discussed in Myths 17 & 18 above that are controversial flawed.”

Its seems both sets are flawed. The Danish studies are mire by conflicts of interest and the others by lack of scientific rigor. This is inconclusive.

I think covering the other myths would involve me repeating earlier points.


The data so far seem inconclusive either way. For my part I don’t think the thimerosal theory can hold up in the absence of the proposed epidemic; I take the position that there is no epidemic. Maybe, ultimately the ball is back in the court of the advocates of this theory. They will have to conclusively and repeatedly show the effectiveness and safety of chelation using research that demonstrates causation, and publish in peer reviewed journals. They will also have to effectively demonstrate an increase in autism exists, and they will have to deal with the ethical questions that arise from attempting to remove autism from children. Until this is done chelation will remain pseudo-scientific.


References

A Photon in the darkness. 2005. http://photoninthedarkness.blogspot.com/2005/09/locked-in-and-threw-away-key.html
Accessed September 6, 2005

Chakrabarti, S., & Fombonne, E. (2001). Pervasive developmental disorders in preschool children. Journal of the American Medical Association, 285, 3093-3099.

Generation Rescue. 2005. http://www.generationrescue.org/index2.html
Accessed October 7, 2005.

Tuesday, September 20, 2005

Reviewing the Autism Prevalence (The Use of the IDEA Data: Part 1)







The Individuals with Disabilities Education Act (IDEA, 1990) was a renaming and a revision of earlier law special education law. The IDEA has since gone through several revisions of its own which can be traced on the US Department of Education website (http://www.ed.gov/policy/speced/guid/idea/idea2004.html).

A yearly accounting of various things including the number of children served in the IDEA service categories are issued by the US department of Special Education to the US Congress every year. It is from these reports that some have begun to track Autism prevalence (The Autism AutoImmunity Project, 2004)

IDEA (1990) created Autism, as a service category in U.S. special education. The IDEA definition is characterized as an assessment of need, not a diagnosis by eligibility alone (Autism Watch, September 15, 2004). This is further complicated by the fact that the States have some freedom to make their diagnostic criteria for Autism more permissive. This seems to be exactly what the States of Oregon and Minnesota have done (Autism Watch, September 15, 2004). These two states have the most students receiving services under the Autism category. In Oregon and Minnesota the diagnostic criteria is permissive when compared to other States. Oregon requires a general agreement from multidisciplinary team that a child meets criteria for Autism, as opposed to an additional separate diagnosis from a professional certified to use the DSM-IV (Autism Watch, September 15, 2004).

The education based data from the IDEA reports to Congress also require some critical thinking. The diagnostic differs from the ICD-10 and the DSM-IV. The US mental health professionals use the DSM-IV. International mental health professionals may use the DSM-IV or the ICD-10. School IEP teams use the IDEA definitions. This is important because, there are discrepancies between the diagnostic systems. A person receiving services under the Autism category of the IDEA may simultaneously be diagnosed with Pervasive Developmental Disorder-Not Otherwise Specified, according to the DSM-IV.

There are other differences as well. In the mental health diagnostic systems, roughly the same percent of persons are diagnosed from their respective racial populations (Fombonne, 2003). So if 1 in 166 White children are diagnosed, 1 in 166 Hispanic children are also going to be diagnosed. This not what we observe in the IDEA data sets.

Figure 4, is created from data provided from IDEAdata.org. The overall population comes from the 2000 census projections. I have added in the Mental Retardation data to give an additional comparison group. The data indicate slightly more White students receiving services for Autism than their overall racial percentage. This is a difference of roughly 5 percentage points. This seems only very moderately discrepant from the (Fombonne, 2003) observation.

This is more pronounced in individual States. Figure 6, represents the data from California. In California, (11%) more White students receive services than their overall racial percentage. At the same time (17%) fewer Hispanic students receive services compared to their overall racial percentage. The differences in racial categories, concerning receiving Autism category services, seems significant in California and discrepant with the (Fombonne, 2003) observation. Due to this discrepancy it is useful to review the mental health numbers supplied by California’s Department of Disability Services and compare it to the census projections for California in 2003. We can look at this in Figure 7. This is extremely interesting because, the Hispanic discrepancy noted in the education numbers are not noted in the DDS numbers.

So what the heck is going on in California and in whole US to some extent? The disappointing part is, it is not possible to know for sure. We can make some statements that are completely valid however, such as “The IDEA data for autism is different from the epidemiology in several important ways.”

When we go on to consider that IDEA definitions and the DSM-IV-TR serve different tasks and utilize different definitions, is this really so surprising?

References

American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.

Autism AutoImmunity Project. (2004).
http://www.taap.info/epidemic.asp.
Accessed September 16, 2005

Autism Watch. Laidler, J. September 15, 2004.
http://www.autism-watch.org/general/edu.shtml.Accessed September 16, 2005.

Day, J. C. (1996). Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. US Bureau of the Census, Current Population Reports, P25-1130, U.S. Government Printing Office, Washington, DC.

Gernsbacher MA, Dawson M, & Goldsmith HH. (2005).Three reasons not to believe in an autism epidemic.Current directions in psychological science, 14 (2), 55-58.

Individuals with Disabilities Education Act. (1990). Public Law 101-476, U.S.C.

World Health Organization. (1992). International Classification of Diseases, 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992.

Wednesday, March 14, 2007

A Review of Discover’s Autism: it’s not just in the head

Overview

“Autism: it’s not just in the head” contain reference to real science and some careful and respectable theoretical statements. It also includes errors of fact, a lack of a skeptical perspective, and defense of credulity.

Introduction

In the April 2007 edition of “Discover”, Jill Neimark presents a thesis that autoimmune and gastrointestinal issues cause the differences in the brain in children with autism. Anecdotes and interviews from doctors and parents who theorize such a connection are given in support of this view.

Review of Graphics

The author offers picture of a distended stomach of a child with autism, and claims that such are comment with children with autism. A claim not supported by well designed research.

The author offers a graphic of Texas comparing the counties with the highest toxicity and the rates of autism. Seemingly these are special education data, of assignment to the autism service category and not recordings of actual cases.

The author offers us two samples of handwriting of a home-schooled autistic child taken a month apart, before and after a child started treatment with antifungal medication. However, the author does not offer us multiple samples let alone a month’s worth of samples. We have no idea of the conditions at the time of these writing, whether the child was hurrying to get the former done in time for a favorite show or activity. These factors would be good to know.

Review of Article

In the article begins with a quote from a mother of two autistic children. I relates to her suicidal thoughts upon learning that her second child also met criteria for autism. The anecdotes of suicidal thoughts of mothers of autistic children has recently been popular making several appearances in documentaries or written work where the mothers advocated a vaccine etiology of autism or a specific treatment modality.

The author writes “and a 2003 report by the Center for Disease Control suggests that as many as one in every 166 children is now on the autism spectrum, while another one in six suffers from a neurodevelopmental delay.”

However the 1 in 6 statistic includes autism as well as other disorder. Furthermore, these disorders include thing like Attention Deficit Hyperactivity Disorder, which are not delays, but disorders or differences. Moreover, 1 in 6, corresponds to 16%. This is the percentage, equal to or below one standard deviation from the mean in a normalized curve. In terms of a given measure such as adaptive behavior or academic achievement, I should (based on the statistics) expect that 1 in 6 children to be at least 1 standard deviation below the average. The confusion here is similar to the confusion that leads to shocked outcries, when it is revealed that ½ of the population perform below average on an IQ test.

Further, it is worth mentioning that many of the advocates of alternative treatments in autism or the vaccine etiology of autism are inconsistent as to whom this 1 in 6 applies to. It can range from describing brain disorders to asthma and food allergies depending on the source.


Another doctor, Martha Herbert states “In spite of so many years of assumptions that a brain disorder like this is not treatable, we’re helping kids get better. So, it can’t just be genetic, prenatal, hardwired, and hopeless”.

It should be asked here for what studies show that any biomedical treatment improves the quality of life for children meeting criteria for autism. At the moment there are no studies that indicate this, perhaps in the future this will change, but it seems that Dr. Herbert’s statement has moved ahead of the data.

In addition, more than one disorder that is genetic and pre-natal offer problems or complications that can be treated, outgrown, or overcome via medical treatment or education. The examples are too numerous to name. What is more, no one who has an even rudimentary familiarity with autism research in the last 20 years would call autism “hopeless”. This is a caricature or straw man fallacy, of those who advocate a theory of idiopathic or genetic etiology of autism.


Dr. Herbert goes on to state “On very striking piece of evidence that many of us have noticed is that when autistic children go in for certain diagnostic tests and are told ot to eat or drink anything ahead of time parents often report that their child’s symptoms improve – until they start eating again after the procedure.”

This statement is reminiscent of one by Dr. Krigsman, who advocates a biomedical treatment approach to autism and a gastrological etiology theory. The endoscopies he performs requires only clear liquid be drunk for a period before hand, so as to offer better vision during the procedure. He mentions that on such a clear liquid diet, the parents claim the child’s behavior improves. Such a diet is devoid of gluten or casein and is somewhat similar the gluten free and casein free diet that Dr. Krigsman advocates. It is notable that this diet did not show improvement in the only controlled study of the subject thus far (Elder et al. 2006). Moreover the majority of parents in the previous study couldn’t tell if their child was on the control diet or the GF/CF diet. Perhaps there are parallels to Hoover & Millch (1994) who found that after giving children artificial sweetener and telling parents it was sugar, the parents rated the children’s behavior significantly worse than controls.

The author mentions an emotional reaction reading the original 11 case studies by Dr. Kanner, the first person to organize autism under a given name. The author finds evidence of autoimmune and gastrointestinal problems within the original case studies. However, this is unfortunate as not every child in those case studies had either sort of problem. This seems like an example of shoe-horning or confirmation bias.

Furthermore, the correlation that struck many more professionals at that time was that many of the children had highly educated parents. This helped give birth to the cold-mother etiology of autism theory, which was propped up, for at least a generation by the lack of organized and consistent biological findings.

At another point Dr. Herbert say’s “I can’t think of it as coincidence anymore that so many autistic kids have a history of food or airborne allergies”. However, these findings are demonstrated within the research. Many typically developing children have a history of environmental allergies as well. Dr. Herbert needs to demonstrate that these occur more frequently in children meeting criteria for autism for this point to stand.

The author states that a ‘Copernican-scale” shift in under way in the world in autism. The author then goes on to site improvement of several children via chelation. The author may indeed by right. However, one may hope that if so, this theory like the theory of a heliocentric universe, will be propped up by excellent proof rather then the anecdotal proofs any faith healer of witch doctor could likewise provide.

The author later cites Dr. Jill James work tracking 8 nchidlren who were treated with folinic acid, trimethylglycine, and methyl-B12. Dr. James found that an increase in markers for methylation and glutathione production within the children. Which is good news, because the researchers theorize that autistic behavior may be related to oxidative stress which might be eliminated by treatment with the above named factor. Unfortunately one of those treatments has been assessed and found to not produce statistically significant results (Deprey et al., 2006). Perhaps these factor in combination will produce notable effect. We will have to see.

A particularly disturbing statement by the author summarizing a statement by Dr. Herbert is: “In other words treat now before the gavel of science strikes a final judgment which might be decades away”. And then the author gives examples of parents ding just that. It seems that the author has assumed what the science will eventually say. This looks like faith based reasoning, not actual logic or science. But, even if the author actually means that at the moment we don’t know what the science will say, but certain treatments anecdotally looks promising so they should be tried, is still poor logic. Some of these treatment are expensive and or dangerous. And even the lowest risk treatment that costs very little money such as the GF/CF diet still takes time and effort on the part of child, the parents, and sometimes that other siblings and grandparents. And diet based intervention are by definition restrictive and can be alienating.

Also, the author points out a anecdote from a mother who’s child broke out in welts after the child was no longer provided with milk. The mother states that is seems that the child was going through a detoxification reaction. The mother seems to have persevered and stuck to the restriction whereas other mothers might have stopped withholding milk or looked for allergens in whatever alternatives where being provided, such as soy milk. This reaction seems similar to what is called a “healing crisis” or “Herxheimer reaction” in alternative medical circles.

Late in the article the author refers to Dr. Yasko’s work concerning polyphorisms and methylation. The author states that Dr. Yasko “seems immune to controversy”, which is a very interesting statement to a skeptic. The author quotes Dr. Yasko (on her decision to focus on treatment rather the scientific publication) as saying “I was on those cliffs you see in the movies and you’re going to jump. You don’t know if there is water below, or enough momentum to get to the other side, but you just jump.” One rather hopes there is enough momentum or at least deep water and that no child will be hurt by Dr. Yasko’s decision to jump off the cliff.

The final statement of the article says “If we can crack the puzzle of autism and be clear about how we did it, that may have huge implications for other chronic environmentally triggered systematic illness. Autism may be a much-needed wake-up call to us all”.

It seems that the author will end as several others have done, will a canary in the coal mine simile.


Conclusion

This article does offer some service in that it explains certain basic research and provides quotes from certain players in the field. Howver, there are factual problems, a reliance on anecdote, and lack of a skeptical voice. Autism may not just be in the head, but if certain treatments are to be used, then research offered must show that "effective biomed treatments" are not just in the advocates' heads.


References

Elder, J, H., Shankar, M, Shuster, J., Theriaque, D., Burns, S., Lindsay Sherrill. (2006). The Gluten-Free, Casein-Free Diet In Autism: Results of A Preliminary Double Blind Clinical Trial. Journal of Autism and Developmental Disorders. 36(3), 413-420.

Deprey LJ, et al "Double-Blind, Placebo-Controlled, Cross-Over Trial of Subcutaneous Methylcobalamin in Autism: Preliminary Results" AACAP 2006; 33:F47.

Hoover, D. W., Milich, R. (1994). Effects of sugar ingestion expectancies on mother-child interactions. Journal of Abnormal Psychology. 22(4), 501-15.

Friday, October 07, 2005

Reviewing the Autism Prevalence (The Epidemiology: Part 2)

If upon reviewing the evidence, we take the stance that there is no epidemic of autism, we can be asked the totally reasonable question of why there appears to be an increase. I have already made some answers concerning the use of the IDEA and California DDS data; in this post I will discuss the change in the epidemiology statistics.

The first thing to note is the difference between studies over the years. In fact wide discrepancy can be observed in the Autistic Disorder specific prevalence per 10,000 persons in the whole world. This includes (.7) calculated by Treffort (1970) using criteria established by Dr. Kanner’s (The person who first described Autism) observations. Sugiyama & Abe (1989) calculated (13) using The Diagnostic and Statistic Manuel-III (DSM) criteria. This can be compared to the greater prevalence of (72.6) calculated by Kadesjo, Gillberg, & Hapberg (1999) using The DSM-III and the Revised International Disease Classification-10 (ICD).

The ICD-10 and the DSM-IV have some discrepancies and although close, are not totally comparable. When viewing studies that offer a rate of all the Pervasive Developmental Disorders, a range can be found from (11.2) per 10,000 persons (Fombonne, & du Mazabrun, 1992), through (67.4) (Bertrand et al., 2001). The problem with these data is that they are calculated from different diagnostics, some of which are more stringent and that they used population samples of different sizes.

Fombonne (2003) lists the prevalence rates of 32 Autism Epidemiology studies from (1966-2001). These are listed in tables (I, III) within (Fombonne, 2003). These data are taken on world wide epidemiology. I calculated the means of these studies by decade, because an increase can be observed this way. It should be noted that the specific decade mean, that a study was placed in this paper, was determined by the year it was published and not the year of the actual data collection.

Fombonne (2003) lists the prevalence rates of 32 Autism Epidemiology studies from (1966-2001). Based on this I calculated the mean in the 1970’s at (3.27) per 10,000 (Standard Deviation =2.24). I calculated this in the 1980’s at (6.98) per 10,000 (SD=5.12). I calculated this in the 1990’s at (19.26) per 10,000 (SD=22.5). I calculated this in the year’s post 1999 at (21.06) per 10,000 (SD=11.78).

The standard deviations are very large in comparison to the means. In the 1990s the standard deviation exceeded the mean. This is an indication of the very discrepant results within this decade. In years post 1999 the standard deviation decreases, showing a greater consistency of the studies.

Using table (3) in the Fombonne (2003) display of studies that calculate Pervasive Developmental Disorder, I calculate the mean in the 1970’s at (13.7) per 10,000 (SD=10.61). I calculated this in the 1980’s at (8.5) per 10,000 (SD=2.96). I calculated this in the 1990’s at (13.75) per 10,000 (SD=3.61). I calculated this in the year’s post 1999 at (49.8) per 10,000 (SD=20.2). In this case the 1970s research seems to have more variation than the more recent decades.

This analysis does not include the most recent epidemiology, specifically Chakrabarti & Fombonne, (2005). However, this study should not significantly affect the standard deviation and mean. It will raise the mean slightly towards the prevalence predicted in Chakrabarti & Fombonne, (2005).

References

American Psychiatric Association. (1980). Diagnostic and Statistical Manual of
Mental Disorders, Third Edition. Washington, DC: American Psychiatric
Association; 1980.

American Psychiatric Association. (1987). Diagnostic and Statistical Manual of
Mental Disorders, Third Edition, Revised. Washington, DC: American
Psychiatric Association; 1980.

American Psychiatric Association. (1994). Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric
Association; 1994.

American Psychiatric Association. (2000). Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American
Psychiatric Association; 1994.

Arvidsson, T., Danielsson, B., Forsberg, P., Gillberg, C., Johansson, M., & Kjellgren, G. (1997). Autism in 3-6 year-old children in a suburb of Goteborg, Sweden. Autism, 2, 163-173.

Autism Diva. Sunday April 27, 2005. http://autismdiva.blogspot.com/
Accessed April 27, 2005

Baird, G., Charman, T., Baron-Cohen, S., et al. (2000). A screening instrument for autism at 18 months of age: a 6 year follow-up study. Journal of American Academy of Child and Adolescent Psychiatry 39, 694-702.

Bertrand, J., Mars, A., Boyle, C., Bove, F., Yeargin-Allsop, M., & Decoufle, P. (2001). Pediatrics, 108, 1155-161.

Boyle CA, Yeargin-Allsop M, Doernberg NS, Holmgreen P. Murphy, CC & Schendel, DE. (1996) Prevalence of selected developmental disabilities in children 3-10 year of age: The Metropolitan Atlanta Developmental Disabilities Surveillance Program. MMWR Morbidity and Mortality Weekly Reports. 45 (SS-2):1-14.

Bryson, S. E., Clark, B. S., & Smith, I. M. (1988). First report of a Canadian epidemiological study of autistic syndromes. Journal of Child Psychology and Psychiatry, 4, 433-445.

Burd, L., Fisher, W., & Kerbeshan, J. (1987). A prevalence study of pervasive developmental disorders in North Dakota. Journal of the American Academy of Child & Adolescent Psychiatry, 26, 5, 700-703.

Chakrabarti, S., & Fombonne, E. (2001). Pervasive developmental disorders in preschool children. Journal of the American Medical Association, 285, 3093-3099.

Chakrabarti, S., Fombonne, E., (2005). Pervasive developmental disorders in preschool children: confirmation of high prevalence. American Journal of Psychiatry, 162(6), 1133-41

Cialdella, P., & Mamelle, N. (1989). An epidemiological study of infantile autism in a French department. Journal of Child Psychology and Psychiatry, 30, 1, 165-175.

Day, J. C. (1996). Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. US Bureau of the Census, Current Population Reports, P25-1130, U.S. Government Printing Office, Washington, DC.

Department of Developmental Services. Changes in the population of persons with autism and pervasive developmental disorders in California's Developmental Services System: 1987 through 1998. Report to the Legislature March 1, 1999 19 pages. http://www.dds.ca.gov1: 1999

Deykin, E. Y., & MacMahon, B. (1979). The incidence of seizures among children with autistic symptoms. American Journal of Psychiatry, 136, 10, 1310-1312.

Ehlers, S., & Gillberg, C. (1993). The epidemiology of Asperger syndrome. A total population study. Journal of Child Psychology and Psychiatry, 34, 1327-1350.

Fombonne, E. (1996). Is the prevalence of autism increasing? Journal of Autism & Developmental Disorders, 6, 673-676.

Fombonne, E. (1997). The prevalence of autism and other pervasive developmental disorders in the UK. Autism, 1, 227-229.

Fombonne, E. (1999). The epidemiology of autism: a review. Psychological Medicine 29, 769-786.

Fombonne, E. (2001). What is the prevalence of Asperger syndrome? Journal of Autism & Developmental Disorders, 31: 3, 363-364.

Fombonne, E. (200l). Is there an epidemic of autism? Pediatrics 107, 411-413.

Fombonne, E. (2002). Prevalence of childhood disintegrative disorder (CDD). Autism 6, 2, 147-155.

Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: an update. Journal of Autism and Developmental Disorders. 33, 365-382.

Fombonne, E., & du Mazaubrun, C. (1992). Prevalence of infantile autism in 4 French regions. Social Psychiatry and Psychiatric Epidemiology, 27, 203-210.

Fombonne, E., du Mazaubrun, C., Cans, C., & Grandjean, H. (1997). Autism and associated medical disorders in a large French epidemiological sample. Journal of the
American Academy of Child & Adolescent Psychiatry, 36: 11, 1561-1569.

Fombonne, E., Simmons, H., Ford, T., et al. (2001). Prevalence of pervasive developmental disorders in the British national survey of child mental health. Journal of the American Academy of Child & Adolescent Psychiatry 40, 820-827.

Gernsbacher MA, Dawson M, & Goldsmith HH. (2005). Three reasons not to believe in an autism epidemic. Current directions in psychological science. In press.

Gillberg, C. (1984). Infantile autism and other childhood psychoses in a Swedish region: epidemiological aspects. Journal of Child Psychology and Psychiatry, 25, 35-43.

Gillberg, C., Steffenburg, S., & Schaumann, H. (1991). Is autism more common now than ten year ago? British Journal of Psychiatry, 158, 403-409.

Individuals with Disabilities Education Act. (1990). Public Law 101-476, U.S.C.

Individuals with Disabilities Education Act Amendments of 1997, P.L. 105-17, 20 U.S.C. 1400 et seq.

Kadesjö, B., Gillberg, C., & Hagberg, B. (1999). Autism and Asperger syndrome in
seven-year old children. A total population study. Journal of Autism &
Developmental Disorders, Vol 29(4), 327-331.

Kielinen, M., Linna, S. L., & Moilanen, I. (2000). Autism in Northern Finland. European Child and Adolescent Psychiatry, 9, 162-167.

Lotter, V. (1966). Epidemiology of autistic conditions in young children: I. Prevalence. Social Psychiatry, 1, 124-137.

Lotter, V. (1967). Epidemiology of autistic conditions in young children: II. Some characteristics of the parents and children. Social Psychiatry, 1, 4, 163-173.

Magnusson, P., & Saemundsen, E. (2001). Prevalence of autism in Iceland. Journal of Autism & Developmental Disorders 31: 153-163.

Mason-Brothers, A., Ritvo, E. R., Pingree, C., Petersen, P. B., Jenson, W. R., McMahon, W. M., Freeman, B. J., Jorde, L. B., Spencer, M. J., Mo, A., & Ritvo, A. (1990). The UCLA-University of Utah epidemiologie survey of autism: prenatal, perinatal, and postnatal factors. Pediatrics, 86,514-519.

Matsuishi, T., Shiotsuki, M., Yoshimura, K., Shoji, H., Imuta, F., & Yamashita, F. (1987). High prevalence of infantile autism in Kurume City, Japan. Journal of Child Neurology, 2, 268-271.

Ritvo, E. R., Freeman, B. J., Pingree, C., Mason-Brothers, A., Jorde, L., Jenson, W. R., McMahon, W. M., Petersen, P. B., Mo, A., & Ritvo, A. (1989). The UCLA-University of Utah epidemiologic survey of autism: prevalence. American Journal of Psychiatry, 146, 2, 194-199.

Rutter, M. (1970). Autistic children: infancy to adulthood. Seminars in Psychiatry, 2, 435-450.

Sponheim, E., & Skjeldal, O. (1998). Autism and related disorders: epidemiological findings in a Norwegian study using ICD-10 diagnostic criteria. Journal of Autism & Developmental Disorders, 28, 217-227.

Steffenburg, S., & Gillberg, C. (1986). Autism and autistic-like conditions in Swedish rural and urban areas: a population study. British Journal of Psychiatry, 149, 81-87.

Steinhausen, H.-C., Göbel, D., Breinlinger, M., & Wohlloben, B. (1986). A community survey of infantile autism. Journal of the American Academy of Child Psychiatry, 25, 2, 186-189.

Sugiyama, T., & Abe, T. (1989). The prevalence of autism in Nagoya, Japan: a total population study. Journal of Autism & Developmental Disorders, 19, 1, 87-96.

Tanoue, Y., Oda, S., Asano, F., & Kawashima, K. (1988). Epidemiology of infantile autism in Southern Ibaraki, Japan: Differences in prevalence in birth cohorts. Journal of Autism & Developmental Disorders, 18, 155-166. 001

Treffert, D. A. (1970). Epidemiology of infantile autism. Archives of General Psychiatry, 22, 431-438.

Volkmar, F. R. (1992). Childhood disintegrative disorder: issues for DSM-IV. Journal of Autism & Developmental Disorders, 22, 625-642.

Volkmar, F. R., & Nelson, D. S. (1990). Seizure disorders in autism. Journal of the American Academy of Child & Adolescent Psychiatry, 1, 127-129.

Volkmar, F. R., Klin, A., Siegel, B., Szatmark, I., Lord, C., Campbell, M., Freeman, B. J., Cicchetti, D. V., Rutter, M., Kline, W., Buitelaar, J., Hattab, Y., Fomhonne, E., Fuentes, J., Werry, J., Stone, W., Kerbeshian, J., Hoshino, Y., Bergman, J., Loveland, K., Szymanski, L., & Towbin. (1994). Field trial for autistic disorder in DSM-IV, American Journal of Psychiatry, 151, 9, 1361-1367.

Webb, E. V. J., Lobo, S., Hervas, A., Scourfield, J., & Fraser, W. I. (1997). The changing prevalence of autistic disorder in a Welsh health district. Developmental Medicine & Child Neurology, 39, 150-152.

Wing, L. (1980). Childhood autism and social class: a question of selection? Britishjournal of Psychiatry, 137, 410-417.

Wing, L. (1993). The definition and prevalence of autism: a review. European Child and Adolescent Psychiatry, 2, 61-74.

Wing, L., Yeates, S. R., Brierly, L. M., & Gould, J. (1976). The prevalence of early childhood autism: comparison of administrative and epidemiological studies. Psychological Medicine, 6, 89-100.

World Health Organization. (1992). International Classification of Diseases, 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992.

Yeargin-Allsopp, M., Rice, C., Karapurka, T., Doernberg, N., Boyle, C., Murphy, C. (2003). Prevalence of autism in a US metropolitan area. Journal of the American Medical Association, 289, 49-89.

Thursday, October 06, 2005

Reviewing the Autism Prevalence (The Epidemiology: Part 1)

The epidemiology establishes the prevalence for the autism spectrum. It can be the most precise method we posses. However it is not without problems or complications. While, these data seem to be the most correct, they still deserve a careful and critical look

The (1) in 166 children, which converts to (60) in 10,000, was a rough estimate given by the Center for Disease Control based on several epidemiological studies they helped conduct (Center for Disease Control, 2005). The Metropolitan Atlanta Developmental Disabilities Surveillance Program (MADDSP) found (20-30) per 10,000 children had an Autism Spectrum Disorder (Boyle, Yeargin-Allsop, Doernberg, Holmgreen, Murphy, & Schendel, 1996). The CDC website also discusses (Bertrand et al., 2001) which found a prevalence of (67) per 10,000 for the autism spectrum and (40) per 10,000 for Autistic Disorder. Only (Bertrand, Mars, Boyle, Bove, Yeargin-Allsop, & Decoufle, 2001) found near (60) per 10,000. The other studies the CDC helped conduct were lower.

Bertrand et al., (2001), like the 3 other studies that produced high prevalence rates (Kadesjo et al., 1999; Baird et al., 2000; Chakrabarti, & Fombonne, 2001) were noted to have small sampling populations (Fombonne, 2003).

I have concerns about the prevalence given by Bertrand et al., (2001). The CDC was aware of a potentially higher incidence in this township as they were going into this city (CDC, 2005; Fombonne, 2003). Originally I had felt that while the data taken from this township might be appropriate for setting the upper limit of autism spectrum prevalence, it might be harmful if applied universally.

Yeargin-Allsopp, Rice, Karapurka, Doernberg, Boyle, Murphy (2003) provides another recent US study to compare to for Autistic Disorder. They found a prevalence of (34) per 10,000. This is lower than the results found by (Bertrand et al., 2001).

However, a recent developments alleviates my concerns and seem to indicate that the (60) per 10,000 is an appropriate prevalence rate. Chakrabarti & Fombonne, (2005) compare a recent cohort to a previous study (measured from 1992-1995) which they conducted in the identical geographical area in the United Kingdom. They conclude that the prevalence rate is high, but stable at (62) per 10,000. And the new study with a sampling population of (10,903) is notably high and resolves my concern about other studies small sampling populations.

The difference between the prevalence rates calculated in the United Kingdom based Chakrabarti & Fombonne, (2005) and United States Bertrand et al., (2001) are insignificant. Dr.s Chakrabarti and Fombonne have convincingly shown that the autism spectrum prevalence rate is high, stable across time, and international. This seriously calls into question the validity of the concept of an epidemic of autism.

References

Baird, G., Charman, T., Baron-Cohen, S., et al. (2000). A screening instrument for autism at 18 months of age: a 6 year follow-up study. Journal of American Academy of Child and Adolescent Psychiatry 39, 694-702.

Bertrand, J., Mars, A., Boyle, C., Bove, F., Yeargin-Allsop, M., & Decoufle, P. (2001). Pediatrics, 108, 1155-161.

Boyle CA, Yeargin-Allsop M, Doernberg NS, Holmgreen P. Murphy, CC & Schendel, DE. (1996) Prevalence of selected developmental disabilities in children 3-10 year of age: The Metropolitan Atlanta Developmental Disabilities Surveillance Program. MMWR Morbidity and Mortality Weekly Reports. 45 (SS-2):1-14.

Chakrabarti, S., & Fombonne, E. (2001). Pervasive developmental disorders in preschool children. Journal of the American Medical Association, 285, 3093-3099.

Chakrabarti, S., Fombonne, E., (2005). Pervasive developmental disorders in preschool children: confirmation of high prevalence. American Journal of Psychiatry, 162(6), 1133-41

Kadesjö, B., Gillberg, C., & Hagberg, B. (1999). Autism and Asperger syndrome in
seven-year old children. A total population study. Journal of Autism & Developmental Disorders, Vol 29(4), 327-331

Yeargin-Allsopp, M., Rice, C., Karapurka, T., Doernberg, N., Boyle, C., Murphy, C. (2003). Prevalence of autism in a US metropolitan area. Journal of the American Medical Association, 289, 49-89.

Reviewing the Autism Prevalence (The Use of the IDEA Data: Part 3)

The final reason I will give not to accept the IDEA autism data as a good predictor of prevalence is the discrepancy to the epidemiology prevalence rates. I consider the two main reasons already given along with this reason, to be adequate to explain why the IDEA data should not be used to calculate autism prevalence.

Based on the data in the annual report to congress, provided by (IDEAdata.org) there are 77,453,872 students ages 3-21 in the US in 2003. There are 163,746 students meeting criteria for Autism ages 3-21 in the US in 2003 (IDEAdata.org). Based on this (Autism Diva, 2005) calculated a prevalence of 1 per 473 students age 3-21; this converts to 21 per 10,000.

This discrepant from Fombonne (2003) and the Center for Disease Controls (2005) upper estimation for pervasive developmental disorders at 1 per 166 or 60 per 10,000.
References

Autism Diva. Sunday April 27, 2005. http://autismdiva.blogspot.com/ Accessed April 27, 2005

Center for Disease Control. February 17, 2005. http://www.cdc.gov/ncbddd/autism/asd_common.htm
Accessed October 6, 2005

Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: an update. Journal of Autism and Developmental Disorders. 33, 365-382.